title: Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intravitreal bevacizumab (IVB) injection in persistent retinopathy secondary to malignant hypertension (MHT).
  
  
  METHODS
  Single IVB injection of 1.25 mg/0.05 ml in 12 cases with persistent retinopathy secondary to MHT more than one month after control of MHT with pre and post injection evaluation of best corrected visual acuity (BCVA) and anatomical outcome up to sixth month and postinjection complications were evaluated.
  
  
  RESULTS
  Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and macular star were documented by photography, angiography, and central macular thickness (CMT) measured by optical coherence tomography (OCT) imaging. Decreased macular edema was the most common finding. Improvement or stabilization of visual acuity was noted in all cases.
  
  
  CONCLUSIONS
  In addition to proper medical management of MHT, IVB injection is an effective and safe approach to treat persistent retinopathy associated with MHT.
authors: Ophthalmology Department, Ain Shams University, Cairo, Egypt.
authors: Abdelrahman Gaber
authors: AG
authors: Salman
keywords: BCVA, best corrected visual acuity; CMT, central macular thickness; IVB, intravitreal bevacizumab; MHT, malignant hypertension; Malignant hypertension; Malignant hypertensive retinopathy; OCT, optical coherence tomography
references: World Health Organ Tech Rep Ser. 1978;(628):7-56
references: 103326
references: Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):233-4
references: 3081083
references: Arch Dis Child. 2001 Nov;85(5):401-3
references: 11668103
references: Am J Med Sci. 1974 Dec;268(6):336-45
references: 4616627
references: Retina. 2006 Nov-Dec;26(9):999-1005
references: 17151486
references: Retina. 2006 Mar;26(3):279-84
references: 16508427
references: Ophthalmology. 2003 Apr;110(4):658-66
references: 12689883
references: Trans Am Ophthalmol Soc. 1997;95:329-48; discussion 348-50
references: 9440178
references: Retina. 2006 Mar;26(3):257-61
references: 16508423
references: Eye (Lond). 2009 Mar;23(3):616-20
references: 18437176